Please try another search
For the fiscal year ended 31 December 2015, Affymetrix, Inc. revenues increased 3% to $359.8M. Net income totaled $10.1M vs. loss of $3.8M. Revenues reflect eBioscience segment increase of 6% to $98.1M, Affymetrix Core segment increase of 2% to $261.7M, United States segment increase of 12% to $193.8M, APAC. segment increase of 12% to $53.8M. Net Income reflects Selling, general and administrative decrease of 1% to $139.2M (expense).
Period Ending: | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|
Total Revenue | 95.57 | 86.53 | 88.97 | 88.72 |
Gross Profit | 61.81 | 55.51 | 57.08 | 54.84 |
Operating Income | 4.91 | -4.02 | 8.53 | 7.29 |
Net Income | 4.06 | -5.34 | 7.01 | 4.39 |
Period Ending: | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|
Total Assets | 546.89 | 547.3 | 538.37 | 503.29 |
Total Liabilities | 207.64 | 214.81 | 202.91 | 201.97 |
Total Equity | 339.25 | 332.49 | 335.46 | 301.32 |
Period Ending: | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | 36.53 | 34.26 | 11.14 | 1.34 |
Cash From Investing Activities | -73.17 | -53.56 | -20.43 | -2.34 |
Cash From Financing Activities | 46.15 | 47.49 | 49.42 | 25.66 |
Net Change in Cash | 8.84 | 27.67 | 39.67 | 24.09 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review